nach oben

Erschienen in:

01.09.2010

Management of prolactinomas in Brazil: an electronic survey

verfasst von: Lucio Vilar, Luciana Ansaneli Naves, Luiz Augusto Casulari, Monalisa Ferreira Azevedo, José Luciano Albuquerque, Fabiano Marcel Serfaty, Flavia R. Pinho Barbosa, Antonio Ribeiro de Oliveira Jr., Renan Magalhães Montenegro, Renan Magalhães Montenegro Jr., Alberto José Santos Ramos, Manuel dos Santos Faria, Nina Rosa C. Musolino, Monica R. Gadelha, Cesar Luiz Boguszewski, Marcello D. Bronstein

Erschienen in: Pituitary | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Dopamine agonists are the treatment of choice for prolactinomas. However, there are still controversies concerning dose, treatment duration and criteria for drug withdrawal in different clinical situations. The aim of this study was to assess diagnostic and therapeutic approaches to prolactinomas among members of the Brazilian Society of Endocrinology and Metabolism (SBEM). SBEM members answered a questionnaire sent by e-mail that included 18 questions related to controversial issues about the management of prolactinomas. Among SBEM members, 721 (approximately 24% of total) answered the questionnaire. Concerning the diagnosis, 38% of the respondents stated that prolactin levels < 100 ng/ml would exclude the presence of a prolactinoma. Most of them favored the screening for macroprolactin in asymptomatic individuals instead of a routine screening (74% vs. 26%). Regarding the treatment, 70% of the respondents chose cabergoline as the drug of choice to treat macroprolactinomas whereas similar proportions advised cabergoline or bromocriptine as the best treatment for microprolactinomas (52% vs. 48%). Only 20% and 34% of respondents favored treatment withdrawal 2–3 years after prolactin normalization in patients with macroprolactinomas and microprolactinomas, respectively. In case of pregnancy, only 58 and 70% of respondents advocated discontinuation of treatment with dopamine agonists in patients with macroprolactinomas and microprolactinomas, respectively. Finally, only 36% would allow breast-feeding without restriction, 44% would restrict it to patients with microprolactinomas and 20% would not recommend it for women with prolactinomas There are several points of disagreement among SBEM members regarding the management of prolactinomas.

Colao A (2009) Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23:575–596CrossRefPubMed

Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265–273CrossRef

Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37:67–99CrossRefPubMed

Kars M, Roelfsema F, Romijn JA, Pereira AM (2006) Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 155:523–534CrossRefPubMed

Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534CrossRefPubMed

Schlechte JA (2007) Long-term management of prolactinomas. J Clin Endocrinol Metab 92:2861–2865CrossRefPubMed

Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R Jr et al (2008) Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 31:436–444PubMed

Verhelst J, Abs R, Maiter D, Vandeweghe M, Velkeniers B, Mockel J et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522CrossRefPubMed

Colao A, Di Sarno A, Landi ML, Cappabianca P, Pivonello R, Volpe R et al (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247–2252CrossRefPubMed

10.

Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909CrossRefPubMed

11.

Vilar L, Naves LA, Gadelha M (2003) Pitfalls in the diagnosis of hyperprolactinemia. Arq Brasil Endocrinol Metab 47:347–357

12.

Toldy E, Löcsei Z, Szabolcs I, Góth MI, Kneffel P, Szöke D, Kovács GL (2003) Macroprolactinemia: the consequences of a laboratory pitfall. Endocrine 22:267–273CrossRefPubMed

13.

Glezer A, Soares CR, Vieira JG, Giannella-Neto D, Ribela MT, Goffin V, Bronstein MD (2006) Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab 91:1048–1055CrossRefPubMed

14.

Gibney J, Smith TP, McKenna TJ (2005) The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 90:3927–3932CrossRefPubMed

15.

Alfonso A, Rieniets KI, Vigersky RA (2006) Incidence and clinical significance of elevated macroprolactin levels in patients with hyperprolactinemia. Endocr Pract 12:275–280PubMed

16.

Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A et al (2002) Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 87:581–588CrossRefPubMed

17.

Strachan MW, Teoh WL, Don-Wauchope AC, Seth J, Stoddart M, Beckett GJ (2003) Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxf) 59:339–346CrossRef

18.

Vilar L, Moura E, Canadas V, Gusmão A, Campos R, Leal E et al (2007) Prevalence of macroprolactinemia among 115 patients with hyperprolactinemia. Arq Brasil Endocrinol Metab 51:86–91

19.

Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418CrossRefPubMed

20.

March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139:835–844PubMed

21.

Koppelman MC, Jaffe MJ, Rieth KG, Caruso RC, Loriaux DL (1984) Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Ann Intern Med 100:115–121PubMed

22.

Sisam DA, Sheehan JP, Sheeler LR (1987) The natural history of untreated microprolactinomas. Fertil Steril 48:67–71PubMed

23.

Passos VQ, Souza JJ, Musolino NR, Bronstein MD (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578–3582CrossRefPubMed

24.

Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033CrossRefPubMed

25.

Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM et al (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26–31CrossRef

26.

Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F et al (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67:426–433CrossRef

27.

Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428–2436CrossRefPubMed

28.

Nelson AT Jr, Tucker HS Jr, Becker DP (1984) Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas. J Neurosurg 61:577–580CrossRefPubMed

29.

Vilar L, Naves LA, Freitas MC, Lima M, Canadas V, Albuquerque JL et al (2007) Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia. Minerva Endocrinol 32:79–86PubMed

30.

Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312:1364–1370CrossRefPubMed

31.

Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8:31–38CrossRefPubMed

32.

Robert E, Musatti L, Piscitelli G, Ferrari CI (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10:333–337CrossRefPubMed

33.

Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S et al (1997) Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 20:547–551PubMed

34.

Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68:66–71CrossRef

35.

Imran SA, Ur E, Clarke DB (2007) Managing prolactin-secreting adenomas during pregnancy. Can Fam Physician 53:653–658PubMed

36.

Bronstein MD, Salgado LR, de Castro Musolino NR (2002) Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 5:99–107CrossRefPubMed

37.

Shewchuk AB, Adamson GD, Lessard P, Ejrin C (1980) The effect of pregnancy on suspected pituitary adenomas after conservative management of ovulation defects associated with galactorrhea. Am J Obstet Gynecol 136:659–666PubMed

38.

Holmgren U, Bergstrand G, Hagenfeldt K, Werner S (1986) Women with prolactinoma—effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol (Copenh) 111:452–459

39.

Zarate A, Canales ES, Alger M, Forsbach G (1979) The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol (Copenh) 92:407–412

40.

Bronstein MD, Musolino NR, Cardim CS, Marino R Jr (1988) Outcome of 52 pregnancies in hyperprolactinemic women. Rev Bras Ginecol Obstet 10:175–178

Titel: Management of prolactinomas in Brazil: an electronic survey
verfasst von: Lucio Vilar
Luciana Ansaneli Naves
Luiz Augusto Casulari
Monalisa Ferreira Azevedo
José Luciano Albuquerque
Fabiano Marcel Serfaty
Flavia R. Pinho Barbosa
Antonio Ribeiro de Oliveira Jr.
Renan Magalhães Montenegro
Renan Magalhães Montenegro Jr.
Alberto José Santos Ramos
Manuel dos Santos Faria
Nina Rosa C. Musolino
Monica R. Gadelha
Cesar Luiz Boguszewski
Marcello D. Bronstein
Publikationsdatum: 01.09.2010
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 3/2010
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-010-0217-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas

Carotid artery visualization during anterior skull base surgery: a novel protocol for neuronavigation

Immediate postoperative cortisol levels accurately predict postoperative hypothalamic–pituitary–adrenal axis function after transsphenoidal surgery for pituitary tumors

Effects of metformin administration on plasma gonadotropin levels in women with infertility, with an in vitro study of the direct effects on the pituitary gonadotrophs

Rosai-Dorfman disease involving the neurohypophysis